Canada markets open in 9 hours 19 minutes

Affimed N.V. (AFMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.9200+0.2100 (+7.75%)
At close: 04:00PM EDT
2.8300 -0.09 (-3.08%)
After hours: 05:27PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.7100
Open2.7100
Bid2.9300 x 2200
Ask3.1300 x 4000
Day's Range2.7100 - 2.9750
52 Week Range2.2300 - 8.6400
Volume1,242,720
Avg. Volume2,060,950
Market Cap436.012M
Beta (5Y Monthly)2.49
PE Ratio (TTM)N/A
EPS (TTM)-0.6590
Earnings DateSept 06, 2022 - Sept 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.84
  • GlobeNewswire

    Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA)

    AFM28 induced potent, effective, and specific anti-tumor activity against CD123-positive cells irrespective of mutational statusStudy demonstrated specific anti-tumor response even at low levels of CD123 expression with no evidence for off-target cytotoxic activity towards CD123-negative healthy bone marrow progenitorsIn vivo studies of an AML murine model demonstrated anti-tumor efficacy; cynomolgus toxicology models showed pharmacodynamic activity with a well-tolerated safety profile suggestin

  • Zacks

    Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates

    Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Affimed Reports First Quarter 2022 Financial Results and Highlights Recent Operational Progress

    AFM13 monotherapy: Completed enrollment in the REDIRECT study for patients with relapsed or refractory PTCL; on track to report topline data in the fourth quarter of 2022AFM13 combination with NK cells: Reported data at AACR 2022 showing a 100% objective response rate (ORR) and an increase in complete responses (CR) from 38%, reported in December, to 62% after a second cycle of therapy in 13 patients at the recommended phase 2 dose (RP2D) with encouraging signals on durabilityAFM24 monotherapy: